Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Clene, Maintains $15 Price Target

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $15 price target.

byBenzinga Newsdesk

February 13, 2023

1 minute read

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $15 price target.

Susquehanna Reiterates Positive on Halliburton, Maintains $57 Price Target

By Benzinga Newsdesk

March 14, 9:54 AM

Susquehanna analyst Charles Minervino reiterates Halliburton (NYSE:HAL) with a Positive and maintains $57 price target.

HAL

Aerovate Therapeutics Q3 EPS $(0.56) Misses $(0.50) Estimate

By Benzinga Newsdesk

November 14, 8:48 AM

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.50) by 12 percent. This is a 115.38 percent decrease over losses of $(0.26) per share

AVTE

Analyst Ratings

The Latest Analyst Ratings for Molina Healthcare

By Benzinga Insights

September 14, 12:00 PM

Over the past 3 months, 5 analysts have published their opinion on Molina Healthcare (NYSE:MOH) stock. These analysts…

MOH

Sundial, Canopy Growth And More: Analyst Examines The Race For The US Cannabis Market

By Nicolas Jose Rodriguez

September 10, 12:48 PM

US legal cannabis sales are predicted to exceed $28 billion in 2023, with promising regulatory developments such as the recommendation to

ACRHF

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $15 Price Target

Related Posts

Susquehanna Reiterates Positive on Halliburton, Maintains $57 Price Target

Aerovate Therapeutics Q3 EPS $(0.56) Misses $(0.50) Estimate

The Latest Analyst Ratings for Molina Healthcare

Sundial, Canopy Growth And More: Analyst Examines The Race For The US Cannabis Market